Loading...
NPI 1851966105 · Plano, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Delta Laboratories LLC is a clinical medical laboratory provider located in Plano, Texas. This profile covers 12 Medicare and 16 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Delta Laboratories LLC |
| Address | 7000 Preston Rd Ste 1500 |
| City | Plano |
| State | TX |
| ZIP | 75024 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 20, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.7M |
| Medicaid | $690.5K |
DELTA LABORATORIES LLC’s billed services are concentrated in molecular and nucleic-acid probe testing: its highest Medicare revenue code is 87798 ($2.9M) and other top Medicare codes include 87900 ($530.9K) and 87799 ($293.8K), all of which are nucleic acid–based assays or genotypic analyses. The code mix and the high volumes reported for these CPTs indicate a clinical medical laboratory operation focused on amplified nucleic acid probe techniques and antiviral resistance/genotypic testing rather than general anatomic pathology or routine chemistry panels.
Revenue is highly concentrated in a small set of tests for both payers: the top 3 Medicare codes by revenue account for 79.2% of this provider’s total Medicare revenue, while the top 3 Medicaid codes by revenue account for 91.6% of this provider’s total Medicaid revenue. This level of concentration signals that a handful of assay types drive the economics of the lab, increasing operational dependence on demand for those specific services.
The provider’s public-payer mix is Medicare-dominant in scale: lifetime Medicare revenue is $4.7M compared with lifetime Medicaid revenue of $690.5K, so Medicare constitutes the bulk of reported public-payer receipts. While both payers are present on file, strategic or contracting decisions will be driven primarily by performance and pricing under Medicare due to its larger revenue footprint.
DELTA is a competitive national performer on several specialized Medicare codes. For 87900 the provider ranks #2 of 94 nationally (99th percentile; labeled an extreme outlier), and for 87798 it ranks #23 of 1319 nationally (98th percentile; notably above typical national volume). These standings indicate the lab is an unusually large national-volume performer for antiviral resistance/genotypic testing and for broader amplified probe assays.
In Medicaid, the provider shows strong but more moderate in-state positioning for the same assay family: 87798 is $568.4K of Medicaid revenue (82.9% of the provider’s Medicaid revenue) and ranks #24 of 243 in-state (90th percentile), while 87900 ranks #3 of 8 in-state (71st percentile) but contributes a much smaller share ($40.2K). In other words, the lab’s molecular testing footprint exists in Medicaid but is materially smaller in dollar scale compared with its Medicare activity.
Payer-level pricing and volume dynamics differ notably by code: for 87798 the average paid per claim is $34 in Medicare (85K claims) versus $65 in Medicaid (8.7K claims), while for 87900 the Medicare average paid per claim is $128 (4.1K claims) versus $17 in Medicaid (2.4K claims). These contrasts show meaningful variation in reimbursement rates and claim volumes between Medicare and Medicaid for the same test families, which can affect margin and referral economics depending on payor mix.
The NPI was enumerated on 2021-05-20 (~5 years ago), a relatively recent market entry given the volumes reported on select codes. Achieving the reported Medicare ranks and claim volumes within about five years suggests rapid scale-up or referral network growth for the lab’s molecular testing services.
Beyond the top two national outliers, several additional PCR/nucleic-acid probe codes show above-typical national volumes (for example, 87799 ranks #7 of 246, 87652 ranks #4 of 89, and 87640 ranks #21 of 1017 in Medicare with 97–98th percentile designations). This pattern of multiple high-percentile ranks across related codes reinforces that the lab’s competitive advantage lies in high-throughput amplified nucleic acid and organism-specific probe testing rather than low-acuity or culture-only services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 84,990 | $30 | $2.9M |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 4,150 | $130 | $530.9K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 7,000 | $40 | $293.8K |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 6,520 | $40 | $267.1K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 6,980 | $30 | $237.2K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 6,550 | $30 | $222.6K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 6,550 | $30 | $222.6K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 410 | $30 | $13.9K |
| 87482 | The lab analyst performs a test to quantify infection with Candida species using nucleic acid probe technique. | 160 | $60 | $8.6K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 130 | $30 | $4.3K |
Showing 1–10 of 12
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 12 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
12 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 21 | 30 | 1,260 | $30 | $430.3K |
| 87798 | 8 | 300 | 790 | $30 | $265.1K |
| 87900 | 1 | 10 | 50 | $130 | $111.5K |
| 87652 | 3 | 20 | 40 | $40 | $73.5K |
| 87481 | 17 | 270 | 150 | $30 | $68.8K |
| 87799 | 1 | 30 | 200 | $40 | $31.8K |
| 87640 | 6 | 250 | 70 | $30 | $25.9K |
| 87653 | 85 | 230 | 70 | $30 | $24K |
| 87500 | 4 | 190 | 80 | $30 | $21.7K |
| 87482 | 3 | 10 | 200 | $50 | $11.5K |
Showing 1–10 of 12
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 8,740 | $70 | $568.4K |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 2,360 | $20 | $40.2K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,970 | $1 | $19.9K |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 4,780 | $1 | $19.1K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 4,990 | $1 | $15K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 4,990 | $1 | $15K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 1,860 | $1 | $5.6K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 220 | $10 | $1.1K |
| 87899 | The lab analyst performs the technical lab test to analyze for an infectious agent by immunoassay with direct optical, meaning visual, observation; use this code for those infectious organisms not… | 270 | $1 | $800 |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 10 | $40 | $420 |
Showing 1–10 of 16
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
16 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 24 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 255 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 264 | 300 | 410 | $20 | $223.4K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 136 | 150 | 320 | $20 | $184K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 10 | 40 | 620 | $20 | $97.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 26 | 170 | 440 | $20 | $93.6K |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 3 | 10 | 1,910 | $20 | $69.7K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 49 | 50 | 380 | $20 | $63.4K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 80 | 140 | 330 | $10 | $62.3K |
| 87511 | The lab analyst performs a test for Gardnerella vaginalis using amplified nucleic acid probe technique. Gardnerella vaginalis, typically causes bacterial vaginosis, an infection of the vagina that… | 53 | 60 | 390 | $10 | $55.3K |
Showing 1–10 of 16
Other providers in the same ZIP code as Delta Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Center For Autism And Related Disorders LLC | TX | Behavior Analyst | $0 | $73M |
| Children's Health System Of Texas | TX | Children's Hospital | $0 | $65.8M |
| Nys Home Health, LLC | TX | Home Health Agency | $0 | $11.1M |
| Joel Lurie | TX | Nurse Practitioner | $2.8M | $0 |
| Hemang Pandya | TX | Retina Specialist (Ophthalmology) Physician | $1.1M | $0 |
| Matthew Adams | TX | Retina Specialist (Ophthalmology) Physician | $873.3K | $0 |
| Medi-lynx Cardiac Monitoring LLC | TX | Physiological Laboratory | $4.4K | $741.4K |
| Andrew Binder | TX | Cardiovascular Disease Physician | $677.6K | $0 |
| Jose Rivera | TX | Cardiovascular Disease Physician | $646.5K | $0 |
| Hao-yu Ren | TX | Cardiovascular Disease Physician | $546.6K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.